KATHLEEN MONEY: Open Payments
NPI 1639840192 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$926 in 28 payments from 13 companies in 2025. Trend: 2023 $1,192 · 2024 $1,445 · 2025 $926
Food & beverage: $926
| Company | Payments | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $277 |
| Amneal Pharmaceuticals LLC | 4 | $105 |
| Neurocrine BioSciences, Inc. | 3 | $90 |
| Eisai Inc. | 3 | $84 |
| Novartis Pharmaceuticals Corporation | 1 | $67 |
| Lilly USA, LLC | 4 | $63 |
| Biogen, Inc. | 3 | $63 |
| ACADIA Pharmaceuticals Inc | 3 | $60 |
| ARGENX US, INC. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
Products named: TREMFYA, LEQEMBI, CREXONT, INGREZZA, COSENTYX, KISUNLA, NUPLAZID, VYVGART HYTRULO.
Industry payments across GA — which companies pay providers there.
